TABLE 2.
Statements reaching consensus in each Delphi round
| Area of Survey | Consensus Achieved | |||
| Round 1 | Round 2 | Consensus Meeting | ||
| Statements That Achieved Consensus | Statements Revised to Achieve Consensus | |||
| Indications in TED | 41% (7/17) | 9% (1/11) | 100% (9/9) | 100% (9/9) |
| Eligible patient populations | 60% (6/10) | 0% (0/3) | 100% (4/4) | 50% (2/4) |
| Dosing | 20% (1/5) | 17% (1/6) | 100% (6/6) | 83% (5/6) |
| Concomitant treatments, medical history, and assessment and monitoring | 25% (9/36) | 29% (8/28) | 100% (26/26) | 55% (11/20) |
| Assessment of response | 30% (3/10) | 33% (3/9) | 100% (6/6) | 86% (5/6) |
| Adverse events | 21% (4/19) | 22% (8/37) | 100% (30/30) | 33% (10/30) |
The number of statements increased from round 1 to round 2 due to the incorporation of expert feedback.
TED, thyroid eye disease.